Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07383688
Recruiting Observational

Neuspera Revision Registry - Follow up Revision Experience and Evaluation of Device Outcomes Metrics

NCT07383688 · tracked via the Priya Life Science USA tracker
Sponsor
Neuspera Medical, Inc
Phase
Observational
Started
2026-04-01
Last updated
2026-10-14

Condition(s) studied

Urinary Urge Incontinence

Investigational drug(s) / intervention(s)

Neuspera Implantable Sacral Neuromodulation System

Neuspera Implantable Sacral Neuromodulation System: Stimulation of the Sacral Nerve

Study summary

Single-arm study where subjects' responses to a questionnaire for the traditional Sacral Neuromodulation (SNM) devices will be compared to the responses regarding the Neuspera SNM System.

Eligibility

Sex
ALL
Min age
22 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Currently have a traditional SNM device and has decided to have the device replaced with the Neuspera SNM System OR previously had an existing traditional SNM implant that was completely removed within the last year 2. Is 22 years of age or older 3. Had documented at least 50% improvement in UUI episodes on a bladder diary with either a stimulation trial or with their traditional system 4. Is a good surgical candidate and qualified to receive the Neuspera SNM System per the device labeling 5. Is capable of participating in all testing and follow-up clinic visits associated with this clinical study. Exclusion Criteria: 1. Has a contraindication for the Neuspera SNM System per the device labeling. 2. Has plans to enroll or is currently enrolled in another investigational device or drug trial during his/her participation in this study

Primary outcome measure(s)

  • Subject Questionnaire — 1 month
    The changes to subject questionnaire responses for the Neuspera SNM system compared to responses regarding traditional SNM systems.

Trial sites (1)

FacilityCityRegionStatus
Specialty Clinical Research of St. Louis St Louis Missouri Recruiting

More Neuspera Medical, Inc. trials in the USA

Neuspera's Implantable Sacral Nerve Stimulation System in Patients With Symptoms of Urinary Urgency Incontinence (UUI) Active, not recruiting
Study of 30-Minute Stimulation With the Neuspera Sacral Neuromodulation (SNM) System Recruiting
Post-Approval Study of the Neuspera Sacral Neuromodulation System Recruiting

Other trials for the same condition

RESTORE: An RCT to Evaluate the Efficacy of the Revi System Active, not recruiting
A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE) Recruiting
Real-World Registry - The Vivally® System Enrolling by invitation
Study of 30-Minute Stimulation With the Neuspera Sacral Neuromodulation (SNM) System Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07383688 on ClinicalTrials.gov ↗ ← All trials in the USA